Mixed connective tissue disease: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Howard C. Berkowitz
(New page: {{seealso|Scleroderma}} Now understood to be a distinct disease, '''mixed connective tissue disease (MCTD)''' is variously considered an overlap between systemic lupus erythematosus, scler...)
 
imported>Howard C. Berkowitz
No edit summary
 
(7 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{subpages}}
{{TOC|right}}
{{seealso|Scleroderma}}
{{seealso|Scleroderma}}
Now understood to be a distinct disease, '''mixed connective tissue disease (MCTD)''' is variously considered an overlap between systemic lupus erythematosus, scleroderma, and polymyositis; a specific subest of  [[scleroderma]] with objective features of other diseases, such as SLE or polymyositis; or a distinct disease entity.
First described in 1972, <ref>{{citation
| title = Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA).
| journal = Am J Med
| year= 1972 | volume = 52 |issue =2 | pages 148-59 3)
| author = Sharp GC; Irvin WS; Tan EM; Gould RG; Holman HR}}</ref> often called  distinct [[rheumatology|rheumatologic]] disease, '''mixed connective tissue disease (MCTD)''' is variously considered an overlap (i.e., '''overlap connective tissue disease''') between [[systemic lupus erythematosus]] (SLE), [[scleroderma]], and [[polymyositis]]; a specific subset of  [[scleroderma]] with objective features of other diseases, such as SLE or polymyositis; or a distinct disease entity. <ref>{{citation
| contribution = Chapter 35: Clinical features of systemic sclerosis
| author = Fredrick M Wigley and Laura K Hummers
| title = Practical Rheumatology
| edition = Third
| publisher = Mosby
| year = 2004
| isbn = 03230299396}}, p. 450</ref> In [[Medical Subject Headings]], it is termed "A syndrome with overlapping clinical features of systemic lupus erythematosus, scleroderma, polymyositis, and Raynaud's phenomenon. The disease is differentially characterized by high serum titers of antibodies to ribonuclease-sensitive extractable (saline soluble) nuclear antigen and a "speckled" epidermal nuclear staining pattern on direct immunofluorescence." <ref>{{MeSH}}</ref>


Most patients with MCTD have [[autoantibody|autoantibodies]] to [[U1 small nuclear ribonucleoprotein]]s (anti-U1 snRNP OR anti-U1 RNP),
From an immunologic standpoint,antibodies against [[ U1 small nuclear ribonucleoprotein]]s (anti-U1 snRNP OR anti-U1 RNP) are characteristic.<ref>{{citation
| journal = eMedicine Specialties > Rheumatology > Systemic Rheumatic Disease
| title =Mixed Connective-Tissue Disease: Overview
| author =Robert W Hoffman and Eric L Greidinger
| date = 7 August 2008
| url = http://emedicine.medscape.com/article/335815-overview}}</ref>
 
A report of two cases suggested  [[tumor necrosis factor-alpha]] inhibitors could aggravate the disease. Antibodies to dual-stranded DNA, diagnostic for lupus, disappeared after the drug was stopped. <ref>{{citation
| title = (Letter) Tumor Necrosis Factor-a Antagonists Induce Lupus-like Syndrome in Patients with Scleroderma Overlap/Mixed Connective Tissue Disease
| journal = J Rheumatol
| url =http://www.jrheum.com/subscribers/03/12/letters.html
| author = Christopher-Stein L, Wigley F
}}</ref>
==References==
{{reflist|2}}

Latest revision as of 13:46, 31 July 2010

This article is developing and not approved.
 Main Article
 Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
https://en.citizendium.org/wiki/index.php?title=Mixed_connective_tissue_disease&printable=yes
This editable Main Article is under development and subject to a disclaimer.
See also: Scleroderma

First described in 1972, [1] often called distinct rheumatologic disease, mixed connective tissue disease (MCTD) is variously considered an overlap (i.e., overlap connective tissue disease) between systemic lupus erythematosus (SLE), scleroderma, and polymyositis; a specific subset of scleroderma with objective features of other diseases, such as SLE or polymyositis; or a distinct disease entity. [2] In Medical Subject Headings, it is termed "A syndrome with overlapping clinical features of systemic lupus erythematosus, scleroderma, polymyositis, and Raynaud's phenomenon. The disease is differentially characterized by high serum titers of antibodies to ribonuclease-sensitive extractable (saline soluble) nuclear antigen and a "speckled" epidermal nuclear staining pattern on direct immunofluorescence." [3]

From an immunologic standpoint,antibodies against U1 small nuclear ribonucleoproteins (anti-U1 snRNP OR anti-U1 RNP) are characteristic.[4]

A report of two cases suggested tumor necrosis factor-alpha inhibitors could aggravate the disease. Antibodies to dual-stranded DNA, diagnostic for lupus, disappeared after the drug was stopped. [5]

References

  1. ↑ Sharp GC; Irvin WS; Tan EM; Gould RG; Holman HR (1972), "Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA).", Am J Med 52 (2)
  2. ↑ Fredrick M Wigley and Laura K Hummers (2004), Chapter 35: Clinical features of systemic sclerosis, Practical Rheumatology (Third ed.), Mosby, ISBN 03230299396, p. 450
  3. ↑ Anonymous (2024), Mixed connective tissue disease (English). Medical Subject Headings. U.S. National Library of Medicine.
  4. ↑ Robert W Hoffman and Eric L Greidinger (7 August 2008), "Mixed Connective-Tissue Disease: Overview", eMedicine Specialties > Rheumatology > Systemic Rheumatic Disease
  5. ↑ Christopher-Stein L, Wigley F, "(Letter) Tumor Necrosis Factor-a Antagonists Induce Lupus-like Syndrome in Patients with Scleroderma Overlap/Mixed Connective Tissue Disease", J Rheumatol
Retrieved from "https://citizendium.org/wiki/index.php?title=Mixed_connective_tissue_disease&oldid=745117"